ロード中...
Golimumab for the treatment of ulcerative colitis
The introduction of therapeutic antibodies against tumor necrosis factor (TNF) had a major impact on the treatment of ulcerative colitis (UC). Infliximab and adalimumab are powerful agents that are used for remission induction and maintenance therapy in UC and have an acceptable safety profile. Howe...
保存先:
| 主要な著者: | , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Dove Medical Press
2014
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3958527/ https://ncbi.nlm.nih.gov/pubmed/24648749 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CEG.S48741 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|